Literature DB >> 18604644

Potential role of type I interferons in the treatment of pituitary adenomas.

Giovanni Vitale1, Michele Caraglia, Peter M van Koetsveld, Paola Maroni, Monica Marra, Annamaria Colao, Steven W J Lamberts, Francesco Cavagnini, Leo J Hofland.   

Abstract

Cytokines, particularly those endowed with pro-inflammatory properties, are known to influence the release of anterior pituitary hormones by a direct and indirect action at the level of pituitary gland and hypothalamus. Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies underline the fact that type I IFNs are involved in the regulation of the immune-endocrine circuitry. Treatment with type I IFNs of patients affected by chronic viral hepatitis, multiple sclerosis and tumors influences the secretion of pituitary hormones. This article reviews the current knowledge about the effects of IFN-alpha and IFN-beta on hypothalamic-pituitary function and describes the potential role of type I IFNs in the treatment of pituitary adenomas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18604644     DOI: 10.1007/s11154-008-9083-3

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  72 in total

Review 1.  Pegvisomant in acromegaly: why, when, how.

Authors:  A Colao; G Arnaldi; P Beck-Peccoz; S Cannavò; R Cozzi; E degli Uberti; L De Marinis; E De Menis; D Ferone; V Gasco; A Giustina; S Grottoli; G Lombardi; P Maffei; E Martino; F Minuto; R Pivonello; E Ghigo
Journal:  J Endocrinol Invest       Date:  2007-09       Impact factor: 4.256

Review 2.  New aspects in the diagnosis and treatment of Cushing disease.

Authors:  M Labeur; M Theodoropoulou; C Sievers; M Paez-Pereda; V Castillo; E Arzt; G K Stalla
Journal:  Front Horm Res       Date:  2006       Impact factor: 2.606

Review 3.  STATs: signal transducers and activators of transcription.

Authors:  J N Ihle
Journal:  Cell       Date:  1996-02-09       Impact factor: 41.582

4.  Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin.

Authors:  Ezequiel Ridruejo; Alejo Flor N Christensen; Oscar G Mando
Journal:  Eur J Gastroenterol Hepatol       Date:  2006-06       Impact factor: 2.566

5.  Interferon-alpha-2a is a potent inhibitor of hormone secretion by cultured human pituitary adenomas.

Authors:  L J Hofland; W W de Herder; M Waaijers; J Zuijderwijk; P Uitterlinden; P M van Koetsveld; S W Lamberts
Journal:  J Clin Endocrinol Metab       Date:  1999-09       Impact factor: 5.958

6.  Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy.

Authors:  Lucile Capuron; Charles L Raison; Dominique L Musselman; David H Lawson; Charles B Nemeroff; Andrew H Miller
Journal:  Am J Psychiatry       Date:  2003-07       Impact factor: 18.112

7.  Increase in serum interleukin-6, plasma ACTH and serum cortisol levels after systemic interferon-alpha administration.

Authors:  H Shimizu; K Ohtani; N Sato; T Nagamine; M Mori
Journal:  Endocr J       Date:  1995-08       Impact factor: 2.349

8.  Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C.

Authors:  E Baudin; P Marcellin; M Pouteau; N Colas-Linhart; J P Le Floch; C Lemmonier; J P Benhamou; B Bok
Journal:  Clin Endocrinol (Oxf)       Date:  1993-12       Impact factor: 3.478

9.  Depending on the time of administration, dexamethasone potentiates or blocks growth hormone-releasing hormone-induced growth hormone release in man.

Authors:  F F Casanueva; B Burguera; M A Tome; L Lima; J A Tresguerres; J Devesa; C Dieguez
Journal:  Neuroendocrinology       Date:  1988-01       Impact factor: 4.914

10.  Ligand-induced association of the type I interferon receptor components.

Authors:  B Cohen; D Novick; S Barak; M Rubinstein
Journal:  Mol Cell Biol       Date:  1995-08       Impact factor: 4.272

View more
  2 in total

1.  HGF/c-met system targeting PI3K/AKT and STAT3/phosphorylated-STAT3 pathways in pituitary adenomas: an immunohistochemical characterization in view of targeted therapies.

Authors:  Maria Trovato; Maria Luisa Torre; Marta Ragonese; Angela Simone; Rosy Scarfì; Valeria Barresi; Giuseppe Giuffrè; Salvatore Benvenga; Flavio F Angileri; Giovanni Tuccari; Francesco Trimarchi; Rosaria Maddalena Ruggeri; Salvatore Cannavò
Journal:  Endocrine       Date:  2013-04-11       Impact factor: 3.633

Review 2.  Pituitary side effects of old and new drugs.

Authors:  Maria Chiara Zatelli; Maria Rosaria Ambrosio; Marta Bondanelli; Ettore Degli Uberti
Journal:  J Endocrinol Invest       Date:  2014-07-29       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.